Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 10 of 33
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Helicobacter Pylori Genotyping Among Mongolian Dyspeptic Patients
    (Mongolian National University of Medical Sciences, 2022-06-30)
    Tserentogtokh Tegshee
    ;
    ; ; ;
    Battulga Adiyasuren
    Objective: The prevalence of H. pylori infection varies significantly and developing countries are found to be the highest in Asia. In the present study, we have aimed to perform a combined analysis of histochemical stains and IHC to confirm the H.pylori infection of patients in 5 different provinces and Ulaanbaatar city, Mongolia. Method: Five hundred and thirty-eight patients were enrolled in this study (142 gastric mucosal atrophy, 333 gastritis and 62 gastroesophageal reflux). Results: 67.1 % of participants had CagA positive and 69.3 % were immunohistochemically positive. All histological results showed that the gastritis group was significantly higher in patients who were positive for H. pylori than in antral-predominant gastritis. By the hematoxylin and eosin staining with May– Giemsa confirmation by IHC, the prevalence of H. pylori infection in the gastric mucosal atrophy group was 62.1 %, while in the gastritis and gastroesophageal reflux group, the rate was 74.3 % and 59.1 %, respectively. Conclusion: CagA sequence profile in each group of patients revealed that 22.6 % of the gastric mucosal atrophy group was ABC type, 43.4 % was ABCC type and 33.9 % was ABTC type. On the other hand, in the gastritis group, the dominant type was ABTC (41.3 %). In the gastroesophageal reflux group, the ABCC type was dominant while 23.1% was the ABC type.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Impact of Hepatitis D Coinfection on the Hepatitis Flare during Chemotherapy for B-Cell Non-Hodgkin Lymphoma
    (Mongolian National University of Medical Sciences, 2020-04-01) ;
    Anir Enkhbat
    ;
    Delgerbat Boldbaatar
    ;
    Khishigjargal Batsukh
    ;
    Altankhuu Murdoj
    Objectives: This study was conducted to determine the effect of Hepatitis B infection with or without D coinfection on the hepatitis flare associated with chemotherapy for B-Cell non-Hodgkin lymphoma. Methods: The hepatitis flare related to the chemotherapy for newly diagnosed B-Cell non-Hodgkin lymphoma was studied in HBV mono-infected and HBV and HDV coinfected patients between 2015 and 2018. Results: Nineteen HBsAg positive patients satisfied the inclusion criteria. In the group with the hepatitis flare, 14.3% were anti-HDV negative and 83.3% were anti-HDV positive (p<.006). Also, the hepatitis flare occurred in all patients where HDV-RNA was detected, while it had occurred in 60% of patients where HDV-RNA was not detected. Conclusion: The hepatitis flare related to chemotherapy occurred more frequently in B-Cell non-Hodgkin lymphoma patients coinfected with HBV and HDV without antiviral prophylaxis, especially when HDV-RNA was detected.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Hepatitis C Associated B-Cell Non-Hodgkin Lymphoma: Impact of Combination Direct-Acting Antivirals and Chemotherapy
    (Mongolian National University of Medical Sciences, 2021-12-31) ;
    Delgerbat Boldbaatar
    ;
    Khishigjargal Batsukh
    ;
    ;
    Objectives: Direct-acting antiviral agents (DAAs) have successfully eradicated chronic hepatitis C virus (HCV) infection. Since chronic HCV is known to have an increased risk of developing B cell non-Hodgkin lymphoma (B-NHL), successful HCV treatment may have virologic, hepatic, and oncologic benefits for B-NHL. Therefore, this study aimed to determine the efficacy of DAAs combined with chemotherapy in B-NHL patients with chronic HCV in Mongolia. Methods: This case-control study included newly diagnosed B-NHL patients with chronic HCV who received DAAs before chemotherapy (with DAAs group). The other is comprised of controls who have been treated by chemotherapy without DAAs. Patients who received courses of DAAs were monitored by the virological and hepatic responses. Results: Eleven patients received DAAs and none of them developed chemotherapy-associated hepatitis flare. Of the DAAs group, during DAAs treatment, 90.9% were clinically stable. In all cases of DAAs in combination with chemotherapy, the Sustained Viral Response (SVR)12 and 24 were 100%. However, 47.4% of those who received DAAs after chemotherapy developed hepatitis flare during chemotherapy. Patients with hepatitis flare had higher serum level of ALT before chemotherapy (15.7 U/L vs. 40.2 U/L; p = 0.014) than those without. Conclusion: DAAs administration results in a significant clinical benefit to B-NHL patients with chronic HCV.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Diagnosis of severe life-threatening decompensated liver cirrhotic complication via cytokines
    (2022-11-14)
    Bayarmaa Ochirkhuree
    ;
    Ayush Khangai
    ;
    ;
    Background: Mongolia is known to be the leading country in the world for liver cancer. The primary cause of liver cancer evidently reported were hepatic virus such as HCV, HBV and HDV. The high mortality of patient with liver cirrhosis is mostly due liver decompensation related complication such as GI bleeding, hepatic failure, infection mostly due to spontaneous bacterial peritonitis (SBP). In this study we aimed to determine the SBP in early stages through examination of cytokines from peritoneal fluid. Methods: Study was conducted among 58 hospitalized patients at the Gastroenterology Center of The FCHM between February to September 2020, who were diagnosed with liver cirrhosis and ascites. Ascites fluid was aspirated following the hospital protocol via abdominal tab with a 16-inch needle guided by ultrasonography on the day 1 of hospitalize and examined for IL-4, IL-6 and INF-gamma. Results: The average age for patients was 52.5 and 31 (53.4%) were males. The hepatic viral cirrhosis was 52 (89.6%). Of the total cases, 28 (48.2%) were CTP-B, and 30 (51.8%) were CTP-C and the mean model for end-stage liver disease score was 20.6. The SBP and non-SBP groups characteristics presented in table 1. Best cut-off value to determine SBP for IL-6 was 629.78 pg/mL with sensitivity and specificity both 100% in Mongolian patients. Conclusions: In patient with liver cirrhosis, elevated IL-6 level (more than 630 pg/mL) in ascites can predict the SBP status as early as possible in limited secondary hospital and to start antibiotic treatment also as early as possible.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Donor’s quality of life after living donor liver transplantation and influencing factors in Mongolia
    (2022-11-15)
    Munkhzaya Chogsom
    ;
    Nasantogtokh Erdenebileg
    ;
    ;
    Background: Improving the quality of living liver donor's postdonation is an important aspect of care quality. In addition, there are many factors that affect the quality of life. In Mongolia, evidence-based information on the quality of life of living donors is few. This study aims to propose the quality of life of living donors who donated organs for liver transplantation and influencing factors.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    P.389: No difference in recurrent hepatocellular carcinoma rates in liver transplanted patients receiving mTOR inhibitors compared to non-mTOR group.
    (Wolters Kluwer, 2024-09-01)
    Anar Ganbold
    ;
    Margad-Erdene Erdenechuluun
    ;
    Bayarmaa Ochirkhuree
    ;
    Urnultsaikhan Ganbold
    ;
    Ulzii-Orshikh Namkhai
    Introduction: A liver transplantation (LT) is a first line therapeutic choice for patients with hepatocellular carcinoma (HCC). Mammalian Target of Rapamycin (mTOR) inhibitors act as immunosuppressant and indicated against HCC recurrence in LT patients. The efficacy of mTOR inhibitors in preventing HCC recurrence remains contentious. Methods: We retrospectively enrolled 45 patients (average age 50, M/F:29/16) who had a history of HCC at the time of LT operation at a single center (2011-2023) and divided into a mTOR and non-mTOR groups. Initial Alfa-fetoprotein (AFP), Protein induced by vitamin K absence-II (PIVKA-II) levels, contrast-enhanced abdominal computer-assisted tomography (CT) scans were compared to most recent results, explant histology was also assessed for HCC extent. Decision to transplant was made based on Milan criteria. Student t-test was used to determine statistical significance (p<0.05). Results: In the mTOR group (n=23, average age 52.7) there were 2 confirmed HCC recurrences with elevated markers and positive CT scans. In the non-mTOR group (n=22, average age 47.4) there was 1 confirmed case of HCC. A recurrence rate of 6.67% was recorded overall, 8.7% and 4.55% for mTOR and non-mTOR (p=0.28), respectively. All three recurrences were detected within 24 months of the operation. For recurrent HCCs, the average levels of PIVKA-II and AFP were 27010mAU/ml and 2842.7ng/ml, respectively. There was no difference in number and mode of pre-LT bridging therapies (TACE or RFA) with regards to recurrence. There were two cases of elevated PIVKA-II without a radiologic confirmation. Conclusion: Adherence to the Milan criteria and application of pre-LT bridging therapies will keep the recurrence rate below 10%. Any possible recurrence will be diagnosed within 24 months of LT. Administration of mTOR inhibitors can be stopped after 2 years as part of the physician-guided minimization of immune suppression regimen.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Ходоодны хорт хавдрын оношилгоонд КТ-ийн шинжилгээний үүрэг
    (2020-05-01)
    Я.Энхтуул
    ;
    Д.Мөнхбаатар
    ;
    Д.Түвшинжаргал
    ;
  • Some of the metrics are blocked by your 
    Item type:Publication,
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Кроны өвчин ба бүдүүн гэдэсний шархлаат үрэвслийн эмнэл зүйн үзүүлэлтийг шүдний тулгуур эдийн үрэвсэлтэй холбон судалсан нь
    (2025-01-01) ; ; ;
    Б.Баярчимэг
    Үндэслэл: Амны хөндий болон бүдүүн гэдэс нь бичил амь, дархлаа судлалын үүднээс холбоотой гэдгийг тогтоосноос хойш сүүлийн жилүүдэд гэдэсний үрэвсэлт өвчин (ГҮӨ) ба шүдний тулгуур эдийн үрэвсэл (ШТЭҮ) хоорондын хамаарлыг судалсан судалгааны ажлууд цөөнгүй хийгдэж байна. Эдгээр судалгааны үр дүнгээс харахад ГҮӨ-д хамаарах Кроны өвчин ба бүдүүн гэдэсний шархлаат үрэвсэл (БГШҮ)-тэй хүмүүст эрүүл хүмүүстэй харьцуулахад ШТЭҮийн тархалт өндөр бөгөөд илүү хүнд хэлбэрийн ШТЭҮ давамгайлж байна. Зорилго: Кроны өвчин, БГШҮ-ийн эмнэл зүйн үзүүлэлт ба ШТЭҮ хоорондын хамаарлыг судлах. Арга, аргачлал: Судалгааг аналитик судалгааны тохиолдол-хяналтын загвар ашиглан 2024 оны 05-р сараас 2025 оны 01-р сарын хооронд УБ Сонгдо эмнэлгийн Хоол боловсруулах эрхтэн судлал-дурангийн тасгаар үйлчлүүлсэн Кроны өвчин эсвэл БГШҮ-тэй, шалгуур хангасан 22 оролцогчийг тохиолдлын бүлэгт; нас болон хүйсээр ижилсүүлсэн харьцангуй эрүүл 44 хүнийг хяналтыг бүлэгт хамруулав. Буйлшүдний эмгэг хөндийн гүн (ЭХГ), эмнэл зүйн холбоосын түвшин (ЭХТ), сэтгүүрдэхэд буйлнаас цус гарах оноо (СБЦГО), амны өнгөрийн оноо (АӨО)-г тодорхойлсон. ШТЭҮ-ийг ЭХТ-ий утга дээр үндэслэн 1-М үе шат болгон ангилсан. Үр дүн: Судалгаанд хамрагдагсдын дундаж нас 42.6±11.6 жил, 40.9% (п=27) нь эрэгтэй, ГҮӨ оношлогдсоноос хойших дундаж хугацаа 1.7 жил байв. ШТЭҮийн тархалт ГҮӨ-тэй бүлэгт 95.5%, хяналтын бүлэгт 75.0% буюу статистик ач холбогдол бүхий ялгаатай байв (р=0.042). III, IV шатны буюу хүнд хэлбэрийн ШТЭҮ нь ГҮӨ-тэй бүлгийн 57.1%-д, хяналтын бүлгийн 30.3%-д нь илэрсэн (р=0.044). Бинар логистик шинжилгээгээр III, IV зэргийн ШТЭҮ үүсэхэд нас (ОР=1.14, р<0.001), АӨИ (ОР=1.09, р<0.001), ГҮӨ (ОР=4.08, р=0.012) тус бүр нөлөөлж байна. Тус хамаарлыг батлах зорилгоор нас, АӨО-г тохируулан шалгахад ГҮӨ-ий хамаарал статистик ач холбогдол бүхий байв (ОР=6.05, р=0.034). Дүгнэлт: Кроны өвчин, БГШҮ нь ШТЭҮ-тэй хамааралтай ба эдгээр хүмүүст нас болон өнгөрийн индексээс үл хамааран III, IV зэргийн ШТЭҮ үүсэх магадлал эрүүл хүмүүстэй харьцуулахад 4-6 дахин өндөр байна.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Коронавируст халдвар (COVID-19)-ын үеийн элэгний эмгэгтэй холбоотой өвчлөлийн үед авах арга хэмжээ
    (2021-06-10)
    Б. Гантуяа
    ;
    ; ; ;
    Н. Баярмаа
    . COVID-19 цар тахлын үеийн энэхүү зааварчилгаа нь нийт гастроэнтеролог болон мэргэшил олгох дамжааны суралцагсадад зориулагдсан. Энэхүү өгүүлэл нь Ковид-19 –ын халдвар оношлогдсон архаг болон цочмог элэгний үрэвсэлтэй өвчтөнд үзүүлэх тусламж үйлчилгээг сайжруулаж зорилгоор хийгдсэн эмч нарт боловсрол олгож буй бүтээл юм. Өгүүллийг АШУҮИС, АУС-ийн ХБЭС-ын Тэнхмийн багш нар боловсруулан гаргалаа. Элэгний архаг өвчтэй хүмүүсийн халдвар авах эрсдэл. Элэгний архаг өвчтэй өвчтөнүүд SARS-CoV-2-ийн халдварт илүү өртөмтгий байгаа эсэх нь тодорхойгүй байна. Гэвч цөсний болон элэгний хучуур эдийн эсүүдэд ангиотензин хувиргадаг фермент 2 рецептор байдаг тул элэг нь SARS-CoV-2-ийн халдварт өртөмтгий байж болно. SARS-CoV-2 вирус нь ACE2 рецептортой холбогдож, бай эрхтнээ гэмтээдэг1-3. Хүнд хэлбэрийн COVID-19 болон нас баралт. Өвчнийг хянах, урьдчилан сэргийлэх төвийн мэдээллэснээр элэгний архаг өвчтэй эсвэл дархлаа дарангуйлагдсан өвчтөнүүдэд COVID19-ийн хүнд хэлбэрийг тусах эрсдэл өндөр байдаг гэж мэдэгдсэн ба энэ талын мэдээлэл судалгаа бага байна4. Ямар нэгэн шалтгаантай элэгний архаг өвчтэй өвчтнүүд. Урьдчилсан мэдээллээс үзэхэд элэгний өвчлөл нь COVID-19-тэй өвчтөнүүдийн хувьд муу үр дүн авчирч байна5-9. COVID-19 өвчтэй 2780 өвчтөнд хийсэн судалгаанд (элэгний архаг өвчтэй 250 өвчтнийг оролцуулсан) элэгний архаг өвчтэй өвчтөнүүдийн нас баралт элэгний өвчлөлгүй хүмүүстэй харьцуулахад харьцангуй өндөр байв ( [RR] 2.8, 95% CI 1.9-4.0)5. Элэгний архаг өвчтэй өвчтөнүүдийн дунд архины бус шалтгаант элэгний эмгэг (NAFLD) ба архины стеатогепатит (NASH) нь хамгийн түгээмэл шалтгаан юм. Мөн элэгний хатууралтай өвчтөнүүд элэгний өвчингүй бүлэгтэй харьцуулахад нас баралтын эрсдэл өндөр байсан (RR 4.6, 95% CI 2.6-8.3). Нас баралтын эрсдэл нь нас, арьсны өнгө, никотины хэрэглээ, биеийн жингийн индекс,